卡比利波西德A通过调节肠道菌群及其来源代谢物来缓解DSS诱导的大肠炎
Huan Zhao1, Xueli Hu2, Shenghong Guan2
1Key Laboratory for Molecular Medicine and Chinese Medicine Preparations, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China; Urology & Nephrology Center, Department of Nephrology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.
卡皮利波西德A (CPS-A) 通过改善肠道屏障功能和调节肠道微生物群,有效治疗性结肠炎 (UC). 这种天然的氨酸为炎症性肠病提供了一个有前途的治疗途径.
科学领域:
- 药理学和自然产品化学化学
- 胃肠道学和免疫学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,其全球发病率正在增加.
- 目前的UC治疗具有显著的副作用,需要新的治疗药物.
- 天然产品的素显示出对大肠炎的干预潜力,Capilliposide A (CPS-A) 显示出抗炎性质.
研究的目的:
- 为了研究Capilliposide A (CPS-A) 在硫酸 (DSS) 诱导的大肠炎小鼠模型上的治疗效果.
- 阐明CPS-A在缓解大肠炎中的作用的基本机制.
主要方法:
- 在DSS诱导的大肠炎小鼠模型中评估CPS-A的疗效和安全性.
- 通过临床症状,组织病理学,炎症性细胞因子量化和上皮屏障功能监测疾病进展.
- 利用非向代谢学和16S rRNA血和肠道内容的测序来分析机制.
主要成果:
- CPS-A治疗显著缓解了结肠炎,改善了临床评分,体重减轻,结肠长度和组织病理损伤.
- 通过调节紧密结蛋白和粘素表达,CPS-A增强了肠道屏障的完整性.
- CPS-A调节肠道微生物群的组成,增加细菌的丰富性和多样性,同时抑制有害细菌和促进有益的细菌.
结论:
- 在临床前模型中,Capilliposide A在治疗性结肠炎方面表现出显著的疗效.
- CPS-A的机制涉及恢复肠道屏障功能和重新平衡肠道微生物群及其代谢物.
- CPS-A代表了一种有前途的天然产品,用于开发新的性结肠炎疗法.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Constipation-Predominant IBS
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents


